Standard Document
36th Edition
Microbiology

CLSI M100

Performance Standards for Antimicrobial Susceptibility Testing

Print copies will be available for shipping mid-February 2026.

CLSI M100 is the gold standard for antimicrobial susceptibility testing, relied upon by laboratories worldwide to guide life-saving clinical decisions. This must-have resource provides the latest, evidence-based breakpoints and quality control parameters, ensuring that laboratories generate accurate, standardized results that clinicians trust for treating seriously ill patients.

Designed for use with CLSI M02 (disk diffusion), CLSI M07 (dilution for aerobic bacteria), and CLSI M11 (dilution for anaerobes), CLSI M100 delivers the most up-to-date tables for drug selection, result interpretation, and quality control (QC).

January 26, 2026
Amy J. Mather, MD, D(ABMM)

{{FormatPrice(currentPrice)}}

Free

{{FormatPrice(nonMemberPrice)}} List Price
This is your member pricing.
Notify Me About New Editions
Abstract

The data in the tables are valid only if the methodologies in CLSI M02, M07, and M11 are followed. These standards contain information about disk diffusion (CLSI M02) and dilution (CLSI M07 and CLSI M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI M02, M07, and M11. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Overview of Changes

CLSI M100-Ed36 replaces CLSI M100-Ed35, published in 2025. Major additions, reformatting, and/or table relocation changes are summarized below, followed by additional noteworthy changes detailed by section/table. Changes to content since the previous edition appear in boldface type; however, minor editorial or formatting changes are not listed here, nor highlighted in boldface type. To learn more about the organization of CLSI M100-Ed36, check the “Instructions for Use.”

Product Details
M100Ed36E
978-1-68440-306-6
436
Authors
Amy J. Mathers, MD, D(ABMM)
James S. Lewis II, PharmD, FIDSA
Alexandra Lynn Bryson, PhD, D(ABMM)
Kevin Alby, PhD, D(ABMM)
April M. Bobenchik, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Tanis Dingle, PhD, D(ABMM), FCCM
German Esparza, MSc
Mark A. Fisher, PhD, D(ABMM)
Joseph Lutgring, MD
Stephanie L. Mitchell, PhD, D(ABMM)
Navaneeth Narayanan, PharmD, MPH
Elizabeth Palavecino, MD
Virginia M. Pierce, MD, FIDSA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Patricia J. Simner, PhD, D(ABMM)
Pranita D. Tamma, MD, MHS
Abstract

The data in the tables are valid only if the methodologies in CLSI M02, M07, and M11 are followed. These standards contain information about disk diffusion (CLSI M02) and dilution (CLSI M07 and CLSI M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tables presented in CLSI M100 represent the most current information for drug selection, interpretation, and QC using the procedures standardized in CLSI M02, M07, and M11. Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Overview of Changes

CLSI M100-Ed36 replaces CLSI M100-Ed35, published in 2025. Major additions, reformatting, and/or table relocation changes are summarized below, followed by additional noteworthy changes detailed by section/table. Changes to content since the previous edition appear in boldface type; however, minor editorial or formatting changes are not listed here, nor highlighted in boldface type. To learn more about the organization of CLSI M100-Ed36, check the “Instructions for Use.”

M100Ed36E
978-1-68440-306-6
436
Authors
Amy J. Mathers, MD, D(ABMM)
James S. Lewis II, PharmD, FIDSA
Alexandra Lynn Bryson, PhD, D(ABMM)
Kevin Alby, PhD, D(ABMM)
April M. Bobenchik, PhD, D(ABMM)
Shelley Campeau, PhD, D(ABMM)
Tanis Dingle, PhD, D(ABMM), FCCM
German Esparza, MSc
Mark A. Fisher, PhD, D(ABMM)
Joseph Lutgring, MD
Stephanie L. Mitchell, PhD, D(ABMM)
Navaneeth Narayanan, PharmD, MPH
Elizabeth Palavecino, MD
Virginia M. Pierce, MD, FIDSA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Patricia J. Simner, PhD, D(ABMM)
Pranita D. Tamma, MD, MHS